Jul 09,2018

WellDoc adds hypertension, weight management to BlueStar; Standalone hypertension product due this year

WellDoc has expanded its BlueStar digital diabetes management platform to include a weight loss feature and a feature for those with both diabetes and hypertension. A standalone product for hypertension is also coming from the company later this year.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jul 09,2018

Prototype uses Google's radar, AI tech to noninvasively measure glucose levels

Researchers from the University of Waterloo have described a proof-of-concept system that uses Google’s Soli — an experimental, radar-based gesture tracker co-developed with Infineon — to track concentrations of glucoses within a solution. With further investigation and adjustment, this prototype technology could potentially be implemented for diabetes patients as a novel noninvasive approach to managing blood glucose levels.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 24,2018

Companion Medical Receives CE Mark

Diabetes care company Companion Medical has just landed a CE mark for its InPen, a smart insulin pen. The connected device has already been FDA-cleared but this latest announcement means that it will be able to go on the EU market.

REGULATORY CE MARK

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jul 30,2018

Abbott Receives FDA Approval of a 14-Day Version of Its Freestyle Libre CGM

Abbott has received FDA approval of a 14-day version of its Freestyle Libre continuous glucose monitoring system. The disposable, fingerstick-free system is comprised of a tiny insertable sensor and a patch roughly the size of a quarter that is worn on the arm. It was first approved by the agency in September 2017, for up to 10 days.

REGULATORY FDA

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 19,2021

My Diabetes My Way now available on G-Cloud 10

MyWay Digital Health announced that its services can now be purchased via the G-Cloud 10 framework which hugely simplifies the contractual and procurement process for organisations wishing to sign up to the award-wining My Diabetes My Way platform.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Jul 02,2018

Insulet Assumes Direct Operations of its Omnipod® Insulin Management System Product Line in Europe

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced as of July 1, it has assumed direct commercial operations in Europe to provide sales, distribution, customer support and product services for its Omnipod System. Insulet has established a dedicated Customer Care team, committed to providing best-in-class support to its large European customer base.

View Analyst & Ambassador Comments
Go to original news
Jul 03,2018

Omnipod® Insulin Management System Now the Preferred Insulin Pump in British Columbia, Canada

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced the Omnipod System has been selected as the preferred insulin pump for individuals with diabetes in the province of British Columbia, Canada, under the expanded British Columbia PharmaCare insulin pump program.

PRODUCT

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Jul 03,2018

Brighter and AFAQ initiate partnership to launch Actiste in the GCC

Brighter AB (publ) and AFAQ Group L.L.C. have entered a partnership to establish a company based in the United Arab Emirates and introduce Actiste® Diabetes Management as a Service into the Gulf Cooperation Council (G.C.C.) region.

COLLABORATION PARTNERSHIP

#product & service

View Analyst & Ambassador Comments
Go to original news
Jul 06,2018

Brighter's Board of Directors has decided to initiate the process to apply for listing its shares on a regulated market

At the board meeting on July 5th 2018, the Board of Directors Brighter AB (publ) formally decided to initiate the process of applying for listing its shares on a regulated market. The listing is expected to take place in 2019.

View Analyst & Ambassador Comments
Go to original news
Jul 09,2018

Insulet Partners with the International Diabetes Federation Europe to Support Advocacy Activities Across the Continent

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it has entered into a partnership with the European Region of the International Diabetes Federation (IDF Europe) to collaborate on regional advocacy activities. This partnership provides broader access for Insulet to more closely engage with the European diabetes community.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES